The world‘s first international trial into second-line HIV therapy has shown two simplified treatments are at least as effective as standard of care.
List view / Grid view
Pfizer’s oral COVID-19 treatment nirmatrelvir will be produced by 35 generic manufacturers to increase supply for low- and middle-income countries.
New European Medicines Agency advice states Paxlovid™ can be used to treat those at high risk of developing severe COVID-19 symptoms.
The license agreement between Pfizer and the Medicines Patent Pool (MPP) will enable access to Pfizer's antiviral candidate in 95 countries.
WHO has said that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon had little or no effect when treating hospitalised patients with COVID-19.
Repurposing existing drugs can be attractive as the process is often less risky, more cost effective and can be undertaken in less time. This article discusses the logic behind drug repurposing and the approaches that are currently being explored.
Researchers found that the combination of lopinavir-ritonavir HIV antivirals led to rapid symptom improvement in COVID-19 patients.
The FDA and EMA have announced which COVID-19 treatments and vaccines are currently in development, as well as how they are supporting clinical trials.